Create
Consult
Collaborate
We can tell your molecule’s story
Our mission is to unlock discoveries and develop solutions for biopharmaceutical companies seeking to overcome substantial scientific challenges by providing data of outstanding quality
Meet us in person at upcoming events
We’re pleased to announce that in 2024 we’ll be exhibiting at the following prestigious conferences:
- ELRIG Drug Discovery in Scotland Forum in Edinburgh: 12 Sep
- Nordic Life Science Days in Malmo: 17-19 Sep
- Festival of Biologics Europe in Basel: 15-17 Oct
- Society for Immunotherapy for Cancer (SITC) in Texas: 6-10 Nov – Booth #538
Our new transformational IndEx-2 system has launched
A powerful, inducible cell system that allows selection of the safest and most efficacious targeted therapies. IndEx-2 is an in vitro cell-based platform that provides inducible expression of any target antigen of interest (TAOI).
- Safety: Gain information on the potential of “on target, off tumour effects” via precise control of TAOI expression to model physiological and pathological expression levels
- Efficacy: Determine the antigen density activation threshold of targeted immunotherapies, including immune cell engagers, ADCs and engineered immune cell therapies
IndEx-2 is an effective tool that can be used to enhance a pre-clinical data package with information that offers a more comprehensive understanding of a targeted drug mechanism of action and functional profile.
Read our latest news and browse our scientific resource articles
Our next immuno-oncology webinar with SelectScience is now available to stream on demand!
We're looking back at the opening of our Discovery Centre and our team's achievements so far.
Using real-time kinetic data to develop a potency bioassay.
Effective IgG1 Fc silencing: characterisation of residual binding and functional activity.